
Fate runs out of excuses
The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.

Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?

Ash 2022 – fast production fails to cure Car-T's problem
Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.

Ash 2022 – following in talquetamab’s slipstream
Roche and Bristol Myers Squibb look to have the industry’s next most advanced assets against GPRC5D.

Ash 2022 – Adicet has a case of déjà vu
Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.

Ash 2022 – Arcellx data secure a Gilead buy-in
Gilead has licensed CART-ddBCMA as this cell therapy continues putting all patients into remission. Can it compete against Carvykti and Tecvayli?

The next cell therapy move takes Astra into neoantigens
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.

Pulling back the curtain on Astrazeneca’s Car-T work
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.